Eli Lilly and Co (LLY) : Employees Retirement System Of Texas scooped up 5,000 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 372,300 shares of Eli Lilly and Co which is valued at $29,865,906.Eli Lilly and Co makes up approximately 0.39% of Employees Retirement System Of Texas’s portfolio.
Other Hedge Funds, Including , Mufg Americas Holdings Corp reduced its stake in LLY by selling 10,763 shares or 8.36% in the most recent quarter. The Hedge Fund company now holds 117,971 shares of LLY which is valued at $9,503,744. Eli Lilly and Co makes up approx 0.32% of Mufg Americas Holdings Corp’s portfolio.Polaris Greystone Financial Group reduced its stake in LLY by selling 215 shares or 2.02% in the most recent quarter. The Hedge Fund company now holds 10,444 shares of LLY which is valued at $863,928. Eli Lilly and Co makes up approx 0.13% of Polaris Greystone Financial Group’s portfolio.Everence Capital Management Inc reduced its stake in LLY by selling 2,740 shares or 7.98% in the most recent quarter. The Hedge Fund company now holds 31,595 shares of LLY which is valued at $2,613,538. Eli Lilly and Co makes up approx 0.78% of Everence Capital Management Inc’s portfolio.
Eli Lilly and Co opened for trading at $79.68 and hit $79.97 on the upside on Tuesday, eventually ending the session at $79.57, with a gain of 0.35% or 0.28 points. The heightened volatility saw the trading volume jump to 34,07,537 shares. Company has a market cap of $87,833 M.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.